GRCL Stock Overview
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Gracell Biotechnologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.25 |
| 52 Week High | US$10.44 |
| 52 Week Low | US$1.40 |
| Beta | -0.35 |
| 1 Month Change | 2.30% |
| 3 Month Change | 93.40% |
| 1 Year Change | 388.10% |
| 3 Year Change | -57.85% |
| 5 Year Change | n/a |
| Change since IPO | -59.10% |
Recent News & Updates
Recent updates
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
Feb 21Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform
Sep 22Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02
Aug 15Gracell Biotechnologies rallies after naming new chief medical officer
Aug 01Gracell names Dr. Samuel Zhang as Chief Business Officer
Jul 19Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Nov 26Gracell ends IPO quiet period with favorable views from analysts
Feb 02Shareholder Returns
| GRCL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | 1.0% | 1.2% |
| 1Y | 388.1% | 0.7% | 24.9% |
Return vs Industry: GRCL exceeded the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: GRCL exceeded the US Market which returned 22.3% over the past year.
Price Volatility
| GRCL volatility | |
|---|---|
| GRCL Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRCL's share price has been volatile over the past 3 months.
Volatility Over Time: GRCL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 314 | William Cao | www.gracellbio.com |
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company’s product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies.
Gracell Biotechnologies Inc. Fundamentals Summary
| GRCL fundamental statistics | |
|---|---|
| Market cap | US$990.82m |
| Earnings (TTM) | -US$69.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.3x
P/E RatioIs GRCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRCL income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥496.98m |
| Earnings | -CN¥496.98m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.4% |
How did GRCL perform over the long term?
See historical performance and comparison